Printer Friendly

EDITEK SUES DISEASE DETECTION INTERNATIONAL RELATIVE TO A LICENSE AGREEMENT TERMINATED NEARLY FIVE YEARS AGO

 BURLINGTON, N.C., Jan. 25 /PRNewswire/ -- EDITEK, Inc. (AMEX: EDI.EC) reported that it has obtained a temporary restraining order against Disease Detection International (NASDAQ: DDIIC) ("DDI") in an action filed in December 1992 asserting violation by DDI of EDITEK's rights to certain technology. A hearing for a preliminary injunction against DDI is scheduled for February 8, 1993. DDI recently filed a cross-complaint against EDITEK in the same action seeking an injunction against EDITEK.
 DDI's cross-complaint is based on a License Agreement with DDI, which EDITEK terminated for cause in June 1988. Pursuant to EDITEK's termination of the Agreement in 1988, DDI on June 7, 1988 returned to EDITEK licensed know-how as required by the Agreement. Contemporaneous with the return of the licensed know-how, DDI issued a press release indicating that it would seek arbitration. During the almost five intervening years, DDI has never attempted to arbitrate the termination of the License Agreement.
 Consistent with termination of the License Agreement, EDITEK has pursued all markets and fields of use for its technology, including those which it licensed to DDI under the terminated Agreement. Significant public disclosures have been made by EDITEK about such matters.
 Following the issuance to EDITEK of Patent No. 5,141,875, Rotary Fluid Manipulator Patent, on August 25, 1992 which describes, among other things, the methodology for the performance of one-step assays, DDI has attempted to revive the terminated License Agreement. The allegations of DDI are frivolous and are totally without merit. EDITEK will vigorously protect all rights to its technology.
 EDITEK, Inc. is an emerging, biodiagnostic company with patented technology for the performance of rapid, on-site assays including one-step assays. The Company currently has products on market or research and development and supply agreements that address the human/clinical, drugs of abuse, U.S. Department of Defense tests for biological substances, veterinary and agrodiagnostics and food safety testing markets.
 -0- 1/25/93
 /CONTACT: Peter Heath, Vice President-Finance and Chief Financial Officer, EDITEK, Inc., 919-226-6311/
 (EDI DDIIC)


CO: EDITEK, Inc.; Disease Detection International ST: North Carolina IN: MTC SU:

CM -- CH008 -- 8584 01/25/93 14:18 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 25, 1993
Words:353
Previous Article:SFFED RELEASES DECEMBER CONSOLIDATED FINANCIAL HIGHLIGHTS
Next Article:FORD ANNOUNCES SERVICE ACTION
Topics:


Related Articles
EDITEK, INC. ANNOUNCES THIRD QUARTER RESULTS
DR. MARK D. DIBNER JOINS EDITEK, INC. BOARD OF DIRECTORS
DISEASE DETECTION INTERNATIONAL SEEKS INJUNCTION AGAINST EDITEK
PRELIMINARY INJUNCTIONS GRANTED TO PRESERVE STATUS QUO PENDING ARBITRATION OF PATENT LICENSE DISPUTE BETWEEN DISEASE DETECTION INTERNATIONAL AND...
EDITEK WINS PRELIMINARY INJUNCTION ROUND IN COURT
EDITEK, INC. AND RHONE-POULENC DIAGNOSTICS, LTD. ESTABLISH JOINT VENTURE
EDITEK ANNOUNCES ADVERSE RULING IN DISEASE DETECTION ARBITRATION
DISEASE DETECTION INTERNATIONAL, INC., WINS ARBITRATION BATTLE WITH EDITEK, INC. OVER VALUABLE PATENT RIGHTS
EDITEK, INC. WINS PATENT INTERFERENCE LITIGATION AGAINST MUREX CORPORATION
EDITEK Announces Restructuring Steps

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters